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The fluoroquinolones are widely used in the treatment of respiratory infections, and the 
potential for bacteria developing resistance to the fluoroquinolones is becoming a concern1. 
Although the low prevalence rate of fluoroquinolone resistant strains are reported (0.15%)2, 
the cases of quinolone-resistant Haemophilus influenzae (H. influenzae) have been 
increasing recently3.  
The mutant prevention concentration (MPC) concept has been suggested as a useful tool for 
guiding the appropriate use of antimicrobial drugs in order to decrease the selection of 
resistant bacteria4. Additionally, the mutant selection window (MSW) is an antimicrobial 
concentration range extending from the minimal concentration required to block the growth 
of wild-type bacteria up to that required to inhibit the growth of the single-step mutant, and 
the upper boundary is also called the MPC1,4. Sitafloxacin is a new fluoroquinolone that has 
been reported to have a broader spectrum, and the greater activity against 
quinolone-resistant strains than that of other quinolones5. The purpose of this study was to 
evaluate the in vitro activity of sitafloxacin and compare its MPC and MSW to those of 





Materials and Methods 
Three H. influenzae strains, Rd, 27995, and 11438, were used to measure the MIC and the 
MPC; the strains 27995 and 11438 with decreasing susceptibility to levofloxacin were 
kindly provided by Meiji Seika Kaisha Ltd. (Tokyo, Japan). Stock solutions of sitafloxacin 
(Daiichi-Sankyo, Tokyo, Japan), levofloxacin (Daiichi-Sankyo, Tokyo, Japan), 
moxifloxacin (Shionogi & Co., Tokyo, Japan), ciprofloxacin (Bayer Corporation, Tokyo, 
Japan), and garenoxacin (Toyama Chemical & Co., Tokyo, Japan) were prepared according 
to the manufacturers’ instructions and frozen at –80°C until needed. Susceptibilities were 
tested in duplicate for each isolate using inocula of 105 CFU / mL and determined by a 
broth dilution method using Haemophilus Test Medium (HTM) according to the Clinical 
and Laboratory Standards Institute (CLSI) recommendation6. 
To identify mutations in the QRDRs of gyrA and parC in these strains, PCR and direct 
DNA sequencing were used according to the method of Vila et al7. The QRDR DNA 
sequencing results were compared with the sequence of strain Rd (GenBank accession no. 
NC_000907), which was used as the wild-type standard strain in this study. The MPC is 





than 1010 cells were applied to agar plates, and generally, it is also defined the lower limit 
of the MSW equal to the MIC5. The MPC methodology was adapted from the method 
outlined by Blondeau et al1. First, the bacterial isolates were grown up on chocolate II agar 
plates (10 plates per isolate) (Nissui Pharmaceutical Co., Tokyo, Japan) and incubated 
overnight at 37°C in 5% CO2. Then, colonies from each strain were transferred from the 
plates to 200 ml of Mueller Hinton II broth (Beckton Dickinson, Oxford, UK) containing 
2% lysed horse blood and 15 µg / ml NAD and then incubated with vigorous shaking for 2 
h at 37°C. Each 200 ml culture was then centrifuged at 5000 rpm for 30 min. The pellets of 
the same strain were combined to make the final suspension of ≥ 3 × 1010 CFU / mL. For 
the MPC determination, 100 l of this concentrated bacterial suspension was used to 
inoculate each fluoroquinolone plates. These plates were incubated at 37°C in 5% CO2 and 
were screened for colonies every 24 h over 96 to 120 h to ensure that the colony number 
had stabilized. 
Results and Discussion 
Table 1 appears to the MPC and MIC ratios which will give the idea of the MSW size. 





was also narrow against the Rd strain (levofloxacin MIC is 0.003 µg/mL) (MPC/MIC ratio; 
2.5). Similarly, the MPCs of sitafloxacin against the strain 27995, with levofloxacin MIC at 
the susceptibility breakpoint, and the strain 11438, with high levofloxacin MIC, were lower 
than the MPCs of the other quinolones tested. Moreover, the MPCs of sitafloxacin were 
lower than the MICs of other fluoroquinolones, and MSW of strain 27995 and 11438 were 
equivalent to or narrower than the MSWs of the other fluoroquinolones (MPC/MIC ratio; 
8.3 and 2, respectively). 
Because the MPC determination assay uses a higher inoculum size (typically 1010 to 1011 
CFU / mL) than MIC, this technique should be further validated prior to adoption of 
clinical therapeutic standards that prevent the selection of antibiotic-resistant mutants. 
Fluoroquinolone resistance may arise largely from sporadic conditions in which abnormally 
low doses or patient characteristics, such as chronic lung disease, cause the drug 
concentration to fall into the MSW and allow the mutation of QRDR. In the present study, 
we demonstrated that sitafloxacin may have a low potential for selecting quinolone 
resistance in H. influenzae mutants. But further studies are warranted to evaluate the 
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